Proposed combination with Baxalta on track with shareholder votes set for May 27 and closing anticipated in early June 2016
April 29, 2016 – Shire plc (“Shire”) (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months ended March 31, 2016.
|Financial Highlights||Q1 2016||Growth(1)||Non GAAP CER(1)(2)|
|Product sales||$1,627 million||+14%||+16%|
|Total revenues||$1,709 million||+15%||+17%|
|Non GAAP operating income||$797 million||+17%||+16%|
|US GAAP operating income from continuing operations||$544 million||+15%|
|Non GAAP EBITDA margin (excluding royalties & other revenues)(3)||46%||0pps(4)|
|US GAAP net income margin(5)||25%||-3pps|
|Non GAAP net income||$632 million||+13%|
|US GAAP net income||$419 million||+2%|
|Non GAAP diluted earnings per ADS||$3.19||+12%||+12%|
|US GAAP diluted earnings per ADS||$2.12||+2%|
|Non GAAP cash generation||$492 million||-5%|
|Non GAAP free cash flow||$338 million||+38%|
|US GAAP net cash provided by operating activities||$390 million||-31%|
(1) Percentages compare to equivalent 2015 period.
(2) On a Constant Exchange Rate (“CER”) basis, which is a Non GAAP measure.
(3) Non GAAP earnings before interest, tax, depreciation and amortization (“EBITDA”) as a percentage of product sales, excluding royalties and other revenues.
(4) Percentage point change (“pps”).
(5) US GAAP net income as a percentage of total revenues.
The Non GAAP financial measures included within this release are explained on pages 25 - 26, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 19 - 22.
First Quarter & Recent Highlights:
(1) Sales prior to February 21, 2015 were recorded by NPS.
Flemming Ornskov, M.D. Chief Executive Officer, commented:
“Shire is off to a strong start in 2016, delivering double-digit product sales and Non GAAP earnings per ADS growth, and advancing our innovative pipeline. We were pleased to report positive Phase 3 topline results for SHP465 in children and adolescents with ADHD, a therapeutic area with significant need for additional treatment options. We are also looking forward to hearing from the FDA by late July regarding lifitegrast, a potential new treatment for dry eye disease.
While we maintain our sharp focus on Shire’s business, we closed the acquisition of Dyax during the quarter and we are making excellent progress with the Baxalta integration planning. Our shareholder vote is scheduled for May 27 and the closing is anticipated to follow in early June. We look forward to officially welcoming our Baxalta colleagues to Shire, and creating a global biotechnology leader focused on rare diseases and other highly specialized conditions.”
|Sarah Elton-Farrfirstname.lastname@example.org||+44 1256 894157|
|Robert Coatesemail@example.com||+44 1256 894874|
|Ian Karpfirstname.lastname@example.org||+1 781 482 9018|
|Michele Galenemail@example.com||+1 781 482-1867|
|Brooke Clarkefirstname.lastname@example.org||+44 1256 894829|
|Gwen Fisheremail@example.com||+1 781 482 9649|
Dial in details for the live conference call for investors at 14:00 BST / 09:00 EDT on April 29, 2016:
|UK dial in:||0808 237 0030 or 020 3139 4830|
|US dial in:||1 866 928 7517 or 1 718 873 9077|
|International Access Numbers:||Click here|
|Live Webcast:||Click here|
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:
other risks and uncertainties detailed from time to time in Shire’s, Dyax’s or Baxalta’s filings with the Securities and Exchange Commission (“SEC”), including those risks outlined in “ITEM 1A: Risk Factors” in Shire’s and Baxalta’s Annual Reports on Form 10-K for the year ended December 31, 2015.
All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.